Tenaya Q2 net loss $29.4M; cash $99.3M; TN-201 gets FDA rare pediatric designation; CFO departs

Tenaya Therapeutics, Inc.

2024-Q2 EPS reported -$0.74

Net loss $29.4M ($0.34/share) vs $33.3M ($0.45) in Q2 2023; R&D expenses $22.6M.
Cash, equivalents & marketable securities $99.3M; sufficient into H2 2025; $45M SVB credit facility available, undrawn.
TN-201 received FDA Rare Pediatric Disease Designation for MYBPC3-associated HCM; interim Phase 1b data expected H2 2024.
TN-401 cleared by UK MHRA to start Phase 1b; 84% of screening volunteers eligible based on low AAV9 antibodies.
CFO Leone Patterson departing Aug 14; CEO Faraz Ali interim PFO; Chihiro Saito interim PAO.

item 2.02 item 9.01 item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change (interim)

Chihiro Saito

Interim Principal Accounting Officer

TNYA · Tenaya Therapeutics, Inc.

Effective: 2024-08-14
Filed: August 8, 2024, 7:59 PM ET

Ms. Chihiro Saito, Tenaya’s Senior Vice President, Accounting and Financial Operations, will assume the role of Interim PAO for the Company

Role change (interim)

Faraz Ali

Interim Principal Financial Officer

TNYA · Tenaya Therapeutics, Inc.

Effective: 2024-08-14
Filed: August 8, 2024, 7:59 PM ET

Faraz Ali, Chief Executive Officer of Tenaya, will become Interim PFO in addition to his role as Chief Executive Officer.

Departed

Leone Patterson

Chief Financial and Business Officer

TNYA · Tenaya Therapeutics, Inc.

Effective: 2024-08-14
Filed: August 8, 2024, 7:59 PM ET

Effective August 14, 2024, upon Ms. Leone Patterson ceasing to be the Chief Financial and Business Officer, Principal Financial Officer (PFO) and Principal Accounting Officer (PAO) for Tenaya

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Chihiro Saito was appointed as Interim Principal Accounting Officer at Tenaya Therapeutics, Inc..

Action: appointed
Role: Interim Principal Accounting Officer

Exact text from the filing

Ms. Chihiro Saito, Tenaya’s Senior Vice President, Accounting and Financial Operations, will assume the role of Interim PAO for the Company

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Faraz Ali was appointed as Interim Principal Financial Officer at Tenaya Therapeutics, Inc..

Action: appointed
Role: Interim Principal Financial Officer

Exact text from the filing

Faraz Ali, Chief Executive Officer of Tenaya, will become Interim PFO in addition to his role as Chief Executive Officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Leone Patterson departed as Chief Financial and Business Officer at Tenaya Therapeutics, Inc..

Action: ceasing to be
Role: Chief Financial and Business Officer

Exact text from the filing

Effective August 14, 2024, upon Ms. Leone Patterson ceasing to be the Chief Financial and Business Officer, Principal Financial Officer (PFO) and Principal Accounting Officer (PAO) for Tenaya

View on SEC.gov

Tenaya Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-093991

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.